These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 19016715)

  • 1. Van-den Berghe's 5q- syndrome in 2008.
    Mohamedali A; Mufti GJ
    Br J Haematol; 2009 Jan; 144(2):157-68. PubMed ID: 19016715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of lenalidomide in the management of myelodysplasia with del 5q.
    Kelaidi C; Eclache V; Fenaux P
    Br J Haematol; 2008 Feb; 140(3):267-78. PubMed ID: 18217896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in RPS14 expression levels during lenalidomide treatment in Low- and Intermediate-1-risk myelodysplastic syndromes with chromosome 5q deletion.
    Oliva EN; Cuzzola M; Nobile F; Ronco F; D'Errigo MG; Laganà C; Morabito F; Galimberti S; Cortelezzi A; Aloe Spiriti MA; Specchia G; Poloni A; Breccia M; Ghio R; Finelli C; Iacopino P; Alimena G; Latagliata R
    Eur J Haematol; 2010 Sep; 85(3):231-5. PubMed ID: 20491881
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromes.
    Heise C; Carter T; Schafer P; Chopra R
    Expert Rev Anticancer Ther; 2010 Oct; 10(10):1663-72. PubMed ID: 20942636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deletion 5q MDS: molecular and therapeutic implications.
    Komrokji RS; Padron E; Ebert BL; List AF
    Best Pract Res Clin Haematol; 2013 Dec; 26(4):365-75. PubMed ID: 24507813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q.
    Nimer SD
    J Clin Oncol; 2006 Jun; 24(16):2576-82. PubMed ID: 16735711
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Morphologic analysis in myelodysplastic syndromes with del(5q) treated with lenalidomide. A Japanese multiinstitutional study.
    Matsuda A; Taniwaki M; Jinnai I; Harada H; Watanabe M; Suzuki K; Yanagita S; Suzuki T; Yoshida Y; Kimura A; Tsudo M; Tohyama K; Takatoku M; Ozawa K
    Leuk Res; 2012 May; 36(5):575-80. PubMed ID: 22172461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of lenalidomide in the treatment of patients with chromosome 5q deletion and other myelodysplastic syndromes.
    Melchert M; Kale V; List A
    Curr Opin Hematol; 2007 Mar; 14(2):123-9. PubMed ID: 17255789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 5q- myelodysplastic syndromes: chromosome 5q genes direct a tumor-suppression network sensing actin dynamics.
    Eisenmann KM; Dykema KJ; Matheson SF; Kent NF; DeWard AD; West RA; Tibes R; Furge KA; Alberts AS
    Oncogene; 2009 Oct; 28(39):3429-41. PubMed ID: 19597464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myelodysplastic syndromes with del(5q): indications and strategies for cytogenetic testing.
    Haferlach C; Bacher U; Tiu R; Maciejewski JP; List A
    Cancer Genet Cytogenet; 2008 Dec; 187(2):101-11. PubMed ID: 19027491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A delayed yet durable response to very short lenalidomide therapy and unexpected clone redistribution in a case of myelodysplastic syndrome with del(5q) and del(20q).
    Xu F; Li X; Chang C; He Q; Zhang Z; Zhang Q; Wu L
    Leuk Res; 2009 Nov; 33(11):e199-202. PubMed ID: 19592091
    [No Abstract]   [Full Text] [Related]  

  • 12. Lenalidomide for treatment of myelodysplastic syndromes: current status and future directions.
    Komrokji RS; List AF
    Hematol Oncol Clin North Am; 2010 Apr; 24(2):377-88. PubMed ID: 20359632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unusual clonal evolution involving 5q in a case of myelodysplastic syndrome with deletion 5q 31 treated with lenalidomide.
    Eclache V; Da Rocha A; Le Roux G; Fenaux P
    Haematologica; 2008 Feb; 93(2):315-6. PubMed ID: 18245660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low RPS14 expression in MDS without 5q - aberration confers higher apoptosis rate of nucleated erythrocytes and predicts prolonged survival and possible response to lenalidomide in lower risk non-5q- patients.
    Wu L; Li X; Xu F; Zhang Z; Chang C; He Q
    Eur J Haematol; 2013 Jun; 90(6):486-93. PubMed ID: 23506134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myelodysplastic syndromes associated with interstitial deletion of chromosome 5q: clinicopathologic correlations and new insights from the pre-lenalidomide era.
    Holtan SG; Santana-Davila R; Dewald GW; Khetterling RP; Knudson RA; Hoyer JD; Chen D; Hanson CA; Porrata L; Tefferi A; Steensma DP
    Am J Hematol; 2008 Sep; 83(9):708-13. PubMed ID: 18634051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A critical review of the molecular pathophysiology of lenalidomide sensitivity in 5q - myelodysplastic syndromes.
    Voutsadakis IA; Cairoli A
    Leuk Lymphoma; 2012 May; 53(5):779-88. PubMed ID: 21955212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lenalidomide--a transforming therapeutic agent in myelodysplastic syndromes.
    List A
    Clin Lymphoma Myeloma; 2009; 9 Suppl 3():S302-4. PubMed ID: 19778857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of lenalidomide in the treatment of myelodysplastic syndromes.
    Komrokji RS; List AF
    Semin Oncol; 2011 Oct; 38(5):648-57. PubMed ID: 21943671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Haematological and cytogenetic responses after only 7 days of Lenalidomide in a patient with myelodysplastic syndrome and chromosome 5q deletion.
    Hadiji Mseddi S; Kallel F; Kassar O; Elloumi M; Jedidi I; Sennana H; Fenaux P
    Leuk Res; 2011 Sep; 35(9):e175-6. PubMed ID: 21658768
    [No Abstract]   [Full Text] [Related]  

  • 20. Lenalidomide in the context of complex karyotype or interrupted treatment: case reviews of del(5q)MDS patients with unexpected responses.
    Giagounidis AA; Haase S; Heinsch M; Göhring G; Schlegelberger B; Aul C
    Ann Hematol; 2007 Feb; 86(2):133-7. PubMed ID: 17111142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.